loading
Denali Therapeutics Inc stock is traded at $21.45, with a volume of 2.22M. It is down -0.19% in the last 24 hours and down -12.16% over the past month. Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
See More
Previous Close:
$21.49
Open:
$21.36
24h Volume:
2.22M
Relative Volume:
2.71
Market Cap:
$3.09B
Revenue:
$340.81M
Net Income/Loss:
$-419.65M
P/E Ratio:
-19.68
EPS:
-1.09
Net Cash Flow:
$-402.10M
1W Performance:
-6.62%
1M Performance:
-12.16%
6M Performance:
+0.23%
1Y Performance:
+1.32%
1-Day Range:
Value
$21.00
$22.21
1-Week Range:
Value
$20.76
$24.15
52-Week Range:
Value
$14.56
$33.33

Denali Therapeutics Inc Stock (DNLI) Company Profile

Name
Name
Denali Therapeutics Inc
Name
Phone
(650) 866-8548
Name
Address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Name
Employee
390
Name
Twitter
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
DNLI's Discussions on Twitter

Compare DNLI with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
DNLI
Denali Therapeutics Inc
21.45 3.09B 340.81M -419.65M -402.10M -2.85
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
397.27 102.31B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
701.85 77.13B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
623.82 37.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
245.44 31.66B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.08 27.11B 3.30B -501.07M 1.03B -2.1146

Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-16-24 Upgrade Stifel Hold → Buy
Oct-10-24 Resumed Raymond James Mkt Perform
Oct-07-24 Downgrade Cantor Fitzgerald Overweight → Neutral
Dec-13-23 Initiated Citigroup Buy
Nov-20-23 Resumed JP Morgan Overweight
Oct-24-23 Resumed Cantor Fitzgerald Overweight
Sep-06-23 Initiated B. Riley Securities Buy
Jan-30-23 Initiated SVB Securities Outperform
Dec-05-22 Initiated Cowen Outperform
Nov-02-22 Upgrade BTIG Research Neutral → Buy
Nov-02-22 Initiated BofA Securities Buy
Jun-23-22 Initiated Berenberg Buy
Dec-10-21 Resumed Raymond James Mkt Perform
Sep-21-21 Initiated Oppenheimer Outperform
Sep-01-21 Initiated SMBC Nikko Outperform
May-18-21 Initiated UBS Buy
Feb-26-21 Reiterated H.C. Wainwright Buy
Feb-10-21 Upgrade Cantor Fitzgerald Neutral → Overweight
Nov-11-20 Reiterated H.C. Wainwright Buy
Oct-16-20 Downgrade BTIG Research Buy → Neutral
Sep-14-20 Resumed JP Morgan Overweight
Aug-20-20 Reiterated H.C. Wainwright Buy
Mar-13-20 Upgrade Evercore ISI In-line → Outperform
Feb-28-20 Upgrade Wedbush Neutral → Outperform
Feb-24-20 Initiated Jefferies Buy
Feb-19-20 Initiated Stifel Hold
Jan-27-20 Upgrade Goldman Neutral → Buy
Sep-26-19 Initiated Wedbush Neutral
Sep-13-19 Initiated Nomura Buy
Aug-09-19 Initiated BTIG Research Buy
Jun-26-19 Initiated H.C. Wainwright Buy
Nov-15-18 Initiated Cantor Fitzgerald Overweight
Nov-12-18 Initiated Janney Buy
Mar-12-18 Downgrade Evercore ISI Outperform → In-line
Jan-02-18 Initiated Evercore ISI Outperform
Jan-02-18 Initiated Goldman Neutral
Jan-02-18 Initiated JP Morgan Overweight
Jan-02-18 Initiated Morgan Stanley Overweight
View All

Denali Therapeutics Inc Stock (DNLI) Latest News

pulisher
Dec 20, 2024

Geode Capital Management LLC Sells 27,061 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat

Dec 20, 2024
pulisher
Dec 19, 2024

Denali Therapeutics Inc. (NASDAQ:DNLI) Stock Holdings Lifted by Barclays PLC - MarketBeat

Dec 19, 2024
pulisher
Dec 17, 2024

Denali Therapeutics upgraded to Buy from Hold at Stifel - Yahoo Finance

Dec 17, 2024
pulisher
Dec 17, 2024

Denali Therapeutics Inc. (NASDAQ:DNLI) Position Reduced by Y Intercept Hong Kong Ltd - MarketBeat

Dec 17, 2024
pulisher
Dec 16, 2024

Denali Therapeutics (NASDAQ:DNLI) Shares Gap UpTime to Buy? - MarketBeat

Dec 16, 2024
pulisher
Dec 16, 2024

Denali Therapeutics (NASDAQ:DNLI) Upgraded to Buy at Stifel Nicolaus - MarketBeat

Dec 16, 2024
pulisher
Dec 16, 2024

Denali Therapeutics Inc. (NASDAQ:DNLI) Receives $38.90 Average PT from Brokerages - MarketBeat

Dec 16, 2024
pulisher
Dec 15, 2024

Nomura Asset Management Co. Ltd. Buys Shares of 65,033 Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat

Dec 15, 2024
pulisher
Dec 15, 2024

State Street Corp Lowers Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat

Dec 15, 2024
pulisher
Dec 13, 2024

When (DNLI) Moves Investors should Listen - Stock Traders Daily

Dec 13, 2024
pulisher
Dec 09, 2024

We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely - Simply Wall St

Dec 09, 2024
pulisher
Dec 08, 2024

Point72 Asset Management L.P. Trims Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat

Dec 08, 2024
pulisher
Dec 08, 2024

Wellington Management Group LLP Has $312.49 Million Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat

Dec 08, 2024
pulisher
Dec 08, 2024

Denali Starts Dosing in Phase II Parkinson's Disease Study - MSN

Dec 08, 2024
pulisher
Dec 06, 2024

Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report? - Yahoo Finance

Dec 06, 2024
pulisher
Dec 06, 2024

Temasek Holdings Private Ltd Lowers Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat

Dec 06, 2024
pulisher
Dec 06, 2024

Holocene Advisors LP Has $2.84 Million Stake in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat

Dec 06, 2024
pulisher
Dec 06, 2024

The Manufacturers Life Insurance Company Has $6.03 Million Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat

Dec 06, 2024
pulisher
Dec 05, 2024

Charles Schwab Investment Management Inc. Trims Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat

Dec 05, 2024
pulisher
Dec 05, 2024

Denali Therapeutics Announces First Participant Dosed in - GlobeNewswire

Dec 05, 2024
pulisher
Dec 05, 2024

Denali Therapeutics Launches Key Phase 2a Trial for Breakthrough Parkinson's Treatment - StockTitan

Dec 05, 2024
pulisher
Dec 04, 2024

26,900 Shares in Denali Therapeutics Inc. (NASDAQ:DNLI) Purchased by Erste Asset Management GmbH - MarketBeat

Dec 04, 2024
pulisher
Dec 03, 2024

Denali Therapeutics Inc. (NASDAQ:DNLI) Position Boosted by Cinctive Capital Management LP - MarketBeat

Dec 03, 2024
pulisher
Dec 03, 2024

Fmr LLC Purchases 7,596,508 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat

Dec 03, 2024
pulisher
Dec 02, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat

Dec 02, 2024
pulisher
Dec 01, 2024

Wasatch Advisors LP Reduces Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat

Dec 01, 2024
pulisher
Dec 01, 2024

Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Bought by Fred Alger Management LLC - MarketBeat

Dec 01, 2024
pulisher
Nov 30, 2024

Denali Therapeutics Getting Closer To Key Technical Measure - MSN

Nov 30, 2024
pulisher
Nov 29, 2024

Algert Global LLC Has $1.42 Million Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat

Nov 29, 2024
pulisher
Nov 29, 2024

29,543 Shares in Denali Therapeutics Inc. (NASDAQ:DNLI) Purchased by Intech Investment Management LLC - MarketBeat

Nov 29, 2024
pulisher
Nov 28, 2024

Fisher Asset Management LLC Buys 69,223 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat

Nov 28, 2024
pulisher
Nov 27, 2024

PTC halts development of ALS drug after trial miss - The Pharma Letter

Nov 27, 2024
pulisher
Nov 27, 2024

Victory Capital Management Inc. Has $1.16 Million Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat

Nov 27, 2024
pulisher
Nov 22, 2024

Objective long/short (DNLI) Report - Stock Traders Daily

Nov 22, 2024
pulisher
Nov 21, 2024

Denali Therapeutics Inc. (NASDAQ:DNLI) Receives $38.90 Consensus PT from Analysts - MarketBeat

Nov 21, 2024
pulisher
Nov 20, 2024

Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging - MSN

Nov 20, 2024
pulisher
Nov 18, 2024

Denali Therapeutics updates bylaws, aligns with SEC rules - Investing.com India

Nov 18, 2024
pulisher
Nov 18, 2024

Denali Therapeutics updates bylaws, aligns with SEC rules By Investing.com - Investing.com UK

Nov 18, 2024
pulisher
Nov 16, 2024

Denali Therapeutics (NASDAQ:DNLI) Trading Down 8.3%Here's What Happened - MarketBeat

Nov 16, 2024
pulisher
Nov 16, 2024

Denali Has A Neurodegenerative Edge Despite Market Skepticism (NASDAQ:DNLI) - Seeking Alpha

Nov 16, 2024
pulisher
Nov 16, 2024

Los Angeles Capital Management LLC Trims Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat

Nov 16, 2024
pulisher
Nov 15, 2024

State of New Jersey Common Pension Fund D Sells 25,613 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat

Nov 15, 2024
pulisher
Nov 13, 2024

Capital Research Global Investors Expands Stake in Denali Therap - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

NLRP3 Protein Inhibitors Clinical Trial Pipeline Appears - GlobeNewswire

Nov 13, 2024
pulisher
Nov 13, 2024

FMR LLC Expands Stake in Denali Therapeutics Inc - GuruFocus.com

Nov 13, 2024
pulisher
Nov 12, 2024

BofA raises Denali Therapeutics target to $34 on BLA plans By Investing.com - Investing.com Canada

Nov 12, 2024
pulisher
Nov 12, 2024

Denali Therapeutics executive sells shares worth $465,286 - Investing.com India

Nov 12, 2024
pulisher
Nov 12, 2024

Denali Therapeutics executive sells shares worth $465,286 By Investing.com - Investing.com Canada

Nov 12, 2024
pulisher
Nov 12, 2024

Baillie Gifford & Co. Sells 417,709 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Principal Financial Group Inc. Increases Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat

Nov 12, 2024

Denali Therapeutics Inc Stock (DNLI) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$17.87
price down icon 2.88%
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
Cap:     |  Volume (24h):